Literature DB >> 19148527

Cell growth regulation through apoptosis by activin in human gastric cancer SNU-16 cell lines.

Young Il Kim1, Byung-Ho Kim, Inkoo Khang, Byung-Nam Cho, Ha Kyu Lee.   

Abstract

Activin has a wide variety of biological functions, including the regulation of cell proliferation and inhibition of tumor cells. We have studied whether activin regulates apoptosis by investigating the effects of activin A on cell proliferation, cell cycle, apoptosis, apoptosis-related gene expression, and caspase activity in SNU-16 cells. Activin A significantly inhibited DNA synthesis and growth suppression in a time-dependent manner in SNU-16 cells. Apoptosis fraction was increased at cell cycle with an accompanying DNA fragmentation. Activin A resulted in a significant time-dependent decrease in Bcl-2 mRNA levels and increase in caspase-3 mRNA levels in SNU-16 cells. No significant difference was observed in Bax mRNA levels. Exposure of cells to activin A induced caspase-3, -8 and -9 activation in SNU-16 cells. Furthermore, co-treatment of activin with the pan-caspase inhibitor Z-VAD-FMK, caspase-3 inhibitor Z-DEVE-FMK, caspase-8 inhibitor Z-IETD-FMK, and caspase-9-inhibitor Z-LEHD-FMK blocked apoptosis of SNU-16 cells. Taken together, our results revealed that activin inhibits the growth of SNU-16 cells by inducing apoptosis through caspase activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148527

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.

Authors:  Zhenhua Wang; Ning Zhang; Ruifeng Song; Ruitai Fan; Liuqin Yang; Liping Wu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Low miR-143/miR-145 Cluster Levels Induce Activin A Overexpression in Oral Squamous Cell Carcinomas, Which Contributes to Poor Prognosis.

Authors:  Andreia Bufalino; Nilva K Cervigne; Carine Ervolino de Oliveira; Felipe Paiva Fonseca; Priscila Campioni Rodrigues; Carolina Carneiro Soares Macedo; Lays Martin Sobral; Marcia Costa Miguel; Marcio Ajudarte Lopes; Adriana Franco Paes Leme; Daniel W Lambert; Tuula A Salo; Luiz Paulo Kowalski; Edgard Graner; Ricardo D Coletta
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

3.  Follistatin is a novel biomarker for lung adenocarcinoma in humans.

Authors:  Fangfang Chen; Ping Ren; Ye Feng; Haiyan Liu; Yang Sun; Zhonghui Liu; Jingyan Ge; Xueling Cui
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

4.  Esophageal squamous cell carcinoma invasion is inhibited by Activin A in ACVRIB-positive cells.

Authors:  Holli A Loomans; Shanna A Arnold; Laura L Quast; Claudia D Andl
Journal:  BMC Cancer       Date:  2016-11-09       Impact factor: 4.430

5.  Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis.

Authors:  Jian Sun; Xuan Liu; Hong Gao; Long Zhang; Qing Ji; Ziyuan Wang; Lihong Zhou; Yan Wang; Hua Sui; Zhongze Fan; Qi Li
Journal:  Oncotarget       Date:  2017-02-14

6.  Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas.

Authors:  J J Staudacher; Alexander Arnold; A A Kühl; M Pötzsch; S Daum; M Winterfeld; E Berg; M Hummel; B Rau; U Stein; C Treese
Journal:  BMC Cancer       Date:  2022-09-05       Impact factor: 4.638

7.  Change in the Gastro-Intestinal Tract by Overexpressed Activin Beta A.

Authors:  Mi-Nyeu Kim; Young Il Kim; Chunghee Cho; Kelly E Mayo; Byung-Nam Cho
Journal:  Mol Cells       Date:  2015-11-24       Impact factor: 5.034

8.  A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor.

Authors:  Yuta Yamada; Ken-Ichi Takayama; Tetsuya Fujimura; Daisaku Ashikari; Daisuke Obinata; Satoru Takahashi; Kazuhiro Ikeda; Shigenori Kakutani; Tomohiko Urano; Hiroshi Fukuhara; Yukio Homma; Satoshi Inoue
Journal:  Cancer Sci       Date:  2016-12-01       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.